News Daily News A ‘Call to Action’ for HF Trials: More Black, Hispanic Patients Caitlin E. Cox March 31, 2022
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Daily News New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts Michael O'Riordan August 06, 2020
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020
News Daily News Recurrent Events Common Among Young Patients With CAD Michael O'Riordan October 11, 2019
News Conference News HFSA 2019 DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF L.A. McKeown September 16, 2019
News Features Wearables Under the Microscope: How New Tech Will Disrupt Patient-Physician Dynamics Marcus A. Banks August 15, 2019
News Daily News Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure Michael O'Riordan May 06, 2019
News Daily News High-Normal Glucose Challenge Tests in Pregnancy May Predict Future Risk of CV Events L.A. McKeown April 11, 2019
News Daily News Ethnic Variations in Lp(a) Concentrations Challenge Current Risk Thresholds Yael L. Maxwell January 25, 2019
News Conference News AHA 2016 Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis Michael O'Riordan November 22, 2016
News Daily News Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT Michael O'Riordan September 29, 2016
News Industry News Leading health organizations collaborate with industry on new initiative to combat growing diabetes and cardiovascular disease threat